Matching articles for "Issue 1309"

Correction: Vancomycin Dosing and Monitoring

   
The Medical Letter on Drugs and Therapeutics • April 20, 2009;  (Issue 1310)
(Med Lett Drugs Ther 2009; 51:25) In the paragraph on dosing, the second-to-last sentence should have said that the new recommendations suggest considering use of an alternative antibiotic when the MIC for the...
(Med Lett Drugs Ther 2009; 51:25) In the paragraph on dosing, the second-to-last sentence should have said that the new recommendations suggest considering use of an alternative antibiotic when the MIC for the infecting organism is ≥2 mg/L, not >2 mg/L.
Med Lett Drugs Ther. 2009 Apr 20;51(1310):32 | Show Full IntroductionHide Full Introduction

Vancomycin Dosing and Monitoring

   
The Medical Letter on Drugs and Therapeutics • April 6, 2009;  (Issue 1309)
Consensus recommendations for dosing and therapeutic monitoring of intravenous (IV) vancomycin (Vancocin, and others) were recently published. IV vancomycin has been used for decades as an alternative to...
Consensus recommendations for dosing and therapeutic monitoring of intravenous (IV) vancomycin (Vancocin, and others) were recently published. IV vancomycin has been used for decades as an alternative to penicillins for treatment of serious infections due to gram-positive cocci. In recent years, the widest use of the drug has been for treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections.
Med Lett Drugs Ther. 2009 Apr 6;51(1309):25 | Show Full IntroductionHide Full Introduction

Deep Brain Stimulation for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • April 6, 2009;  (Issue 1309)
Deep brain stimulation (DBS) is increasingly used to treat advanced Parkinson's disease (PD), but few controlled clinical trials have been published. New evidence from a large controlled study has recently...
Deep brain stimulation (DBS) is increasingly used to treat advanced Parkinson's disease (PD), but few controlled clinical trials have been published. New evidence from a large controlled study has recently become available.
Med Lett Drugs Ther. 2009 Apr 6;51(1309):26-7 | Show Full IntroductionHide Full Introduction

Valproic Acid Delayed Release (Stavzor)

   
The Medical Letter on Drugs and Therapeutics • April 6, 2009;  (Issue 1309)
The FDA has approved a delayed-release capsule formulation of valproic acid (VPA; Stavzor - Noven Therapeutics) for all of the indications for which divalproex sodium (Depakote, and others; Depakote ER) is...
The FDA has approved a delayed-release capsule formulation of valproic acid (VPA; Stavzor - Noven Therapeutics) for all of the indications for which divalproex sodium (Depakote, and others; Depakote ER) is approved: monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures, and adjunctive therapy in patients with multiple seizure types that include absence seizures; acute treatment of manic episodes associated with bipolar disorder; and prophylaxis of migraine headaches. In addition, valproate (valproic acid or divalproex sodium) is considered a drug of choice for treatment of other types of seizures including generalized tonic-clonic, myotonic and atonic seizures.
Med Lett Drugs Ther. 2009 Apr 6;51(1309):27-8 | Show Full IntroductionHide Full Introduction